B-Cell Responses to Sars-Cov-2 mRNA Vaccines

Most vaccines against viral pathogens protect through the acquisition of immunological memory from long-lived plasma cells that produce antibodies and memory B cells that can rapidly respond upon an encounter with the pathogen or its variants. The COVID-19 pandemic and rapid deployment of effective...

Descripción completa

Detalles Bibliográficos
Autores principales: Kardava, Lela, Buckner, Clarisa M., Moir, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pathogens and Immunity 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9836209/
https://www.ncbi.nlm.nih.gov/pubmed/36655200
http://dx.doi.org/10.20411/pai.v7i2.550
_version_ 1784868817091952640
author Kardava, Lela
Buckner, Clarisa M.
Moir, Susan
author_facet Kardava, Lela
Buckner, Clarisa M.
Moir, Susan
author_sort Kardava, Lela
collection PubMed
description Most vaccines against viral pathogens protect through the acquisition of immunological memory from long-lived plasma cells that produce antibodies and memory B cells that can rapidly respond upon an encounter with the pathogen or its variants. The COVID-19 pandemic and rapid deployment of effective vaccines have provided an unprecedented opportunity to study the immune response to a new yet rapidly evolving pathogen. Here we review the scientific literature and our efforts to understand antibody and B-cell responses to SARS-CoV-2 vaccines, the effect of SARSCoV-2 infection on both primary and secondary immune responses, and how repeated exposures may impact outcomes.
format Online
Article
Text
id pubmed-9836209
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Pathogens and Immunity
record_format MEDLINE/PubMed
spelling pubmed-98362092023-01-17 B-Cell Responses to Sars-Cov-2 mRNA Vaccines Kardava, Lela Buckner, Clarisa M. Moir, Susan Pathog Immun Review Most vaccines against viral pathogens protect through the acquisition of immunological memory from long-lived plasma cells that produce antibodies and memory B cells that can rapidly respond upon an encounter with the pathogen or its variants. The COVID-19 pandemic and rapid deployment of effective vaccines have provided an unprecedented opportunity to study the immune response to a new yet rapidly evolving pathogen. Here we review the scientific literature and our efforts to understand antibody and B-cell responses to SARS-CoV-2 vaccines, the effect of SARSCoV-2 infection on both primary and secondary immune responses, and how repeated exposures may impact outcomes. Pathogens and Immunity 2022-12-09 /pmc/articles/PMC9836209/ /pubmed/36655200 http://dx.doi.org/10.20411/pai.v7i2.550 Text en Copyright © 2022 Pathogens and Immunity https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Review
Kardava, Lela
Buckner, Clarisa M.
Moir, Susan
B-Cell Responses to Sars-Cov-2 mRNA Vaccines
title B-Cell Responses to Sars-Cov-2 mRNA Vaccines
title_full B-Cell Responses to Sars-Cov-2 mRNA Vaccines
title_fullStr B-Cell Responses to Sars-Cov-2 mRNA Vaccines
title_full_unstemmed B-Cell Responses to Sars-Cov-2 mRNA Vaccines
title_short B-Cell Responses to Sars-Cov-2 mRNA Vaccines
title_sort b-cell responses to sars-cov-2 mrna vaccines
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9836209/
https://www.ncbi.nlm.nih.gov/pubmed/36655200
http://dx.doi.org/10.20411/pai.v7i2.550
work_keys_str_mv AT kardavalela bcellresponsestosarscov2mrnavaccines
AT bucknerclarisam bcellresponsestosarscov2mrnavaccines
AT moirsusan bcellresponsestosarscov2mrnavaccines

Ejemplares similares